Saltar al contenido
Merck
  • Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.

Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.

Bioorganic & medicinal chemistry letters (2010-11-16)
Eugen F Mesaros, Jason P Burke, Jonathan D Parrish, Benjamin J Dugan, Andrew V Anzalone, Thelma S Angeles, Mark S Albom, Lisa D Aimone, Matthew R Quail, Weihua Wan, Lihui Lu, Zeqi Huang, Mark A Ator, Bruce A Ruggeri, Mangeng Cheng, Gregory R Ott, Bruce D Dorsey
RESUMEN

The synthesis and biological evaluation of potent and selective anaplastic lymphoma kinase (ALK) inhibitors from a novel class of 2,4-diaminopyrimidines, incorporating 2,3,4,5-tetrahydro-benzo[d]azepine fragments, is described. An orally bioavailable analogue (18) that displayed antitumor efficacy in ALCL xenograft models in mice was identified and extensively profiled.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
2,4-Diaminopyrimidine, 98%